{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:45:51Z","timestamp":1793144751551,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd001447.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2012,3,14]],"date-time":"2012-03-14T00:00:00Z","timestamp":1331683200000}}],"reference-count":51,"publisher":"Wiley","issue":"3","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd001447.pub3","type":"journal-article","created":{"date-parts":[[2012,3,9]],"date-time":"2012-03-09T10:38:39Z","timestamp":1331289519000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":407,"title":["Riluzole for amyotrophic lateral sclerosis (ALS)\/motor neuron disease (MND)"],"prefix":"10.1002","volume":"2012","author":[{"given":"Robert G","family":"Miller","sequence":"first","affiliation":[{"name":"California Pacific Medical Center; Forbes Norris ALS Research Center; 2324 Sacramento Street, Suite 150 San Francisco USA 94115"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J D","family":"Mitchell","sequence":"additional","affiliation":[{"name":"Royal Preston Hospital; Preston MND Care & Research Centre; Preston UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan H","family":"Moore","sequence":"additional","affiliation":[{"name":"California Pacific Medical Center; Research Institute; 475 Brannan St Suite 220 San Francisco CA USA 94107"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,3,14]]},"reference":[{"issue":"9","key":"10.1002\/14651858.CD001447.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJM199403033300901","article-title":"A controlled trial of riluzole in amyotrophic lateral sclerosis. The ALS\/Riluzole Study Group","volume":"330","author":"Bensimon","year":"1994","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD001447.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s004150200071","article-title":"A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis","volume":"249","author":"Bensimon","year":"2002","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD001447.pub3-BIB0003|cit3","unstructured":"Meininger V Lacomblez L Bensimon G Unpublished report: controlled trial of riluzole in patients with advanced ALS RP 54272-302 1995"},{"issue":"9013","key":"10.1002\/14651858.CD001447.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/S0140-6736(96)91680-3","article-title":"Dose-ranging study of riluzole in amyotrophic lateral sclerosis","volume":"347","author":"Lacomblez","year":"1996","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD001447.pub3-BIB0005|cit5","first-page":"851","article-title":"Efficacy and safety of riluzole in patients with amyotrophic lateral sclerosis: double-blind placebo-controlled study in Japan","volume":"182","author":"Yanagisawa","year":"1997","journal-title":"Igakuno Ayumi"},{"key":"10.1002\/14651858.CD001447.pub3-BIB0006|cit6","first-page":"33","article-title":"Open label study of riluzole for the treatment of amyotrophic lateral sclerosis","volume":"8","author":"Arriada-Mendicoa","year":"1999","journal-title":"Revista Ecuatoriana de Neurologia"},{"issue":"4","key":"10.1002\/14651858.CD001447.pub3-BIB0007|cit7","first-page":"357","article-title":"Interest of a computerized ALS database in the diagnosis and follow-up of patients with ALS","volume":"156","author":"Couratier","year":"2000","journal-title":"Revue Neurologique"},{"issue":"1-2","key":"10.1002\/14651858.CD001447.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0022-510X(99)00225-7","article-title":"The effect of riluzole in amyotrophic lateral sclerosis: a study with cortical stimulation","volume":"169","author":"Desiato","year":"1999","journal-title":"Journal of Neurological Sciences"},{"issue":"5","key":"10.1002\/14651858.CD001447.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00702-004-0220-1","article-title":"High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study","volume":"112","author":"Graf","year":"2005","journal-title":"Journal of Neural Transmission"},{"issue":"8","key":"10.1002\/14651858.CD001447.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1097\/00001756-199806010-00016","article-title":"Recovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy","volume":"9","author":"Kalra","year":"1998","journal-title":"Neuroreport"},{"issue":"2","key":"10.1002\/14651858.CD001447.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/14660820410019602","article-title":"Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: Results of two phase III trials","volume":"5","author":"Meininger","year":"2004","journal-title":"Amyotrophic Lateral Sclerosis & Other Motor Neuron Disorders"},{"key":"10.1002\/14651858.CD001447.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/14660820500396984","article-title":"Audit of outcomes in motor neuron disease (MND) patients treated with riluzole","volume":"7","author":"Mitchell","year":"2006","journal-title":"Amyotrophic lateral sclerosis and other motor neuron disorders"},{"issue":"1","key":"10.1002\/14651858.CD001447.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1046\/j.1529-8027.2000.00513-45.x","article-title":"An open study of riluzole versus riluzole plus gabapentin in amyotrophic lateral sclerosis","volume":"5","author":"Palma","year":"2000","journal-title":"Journal of the Peripheral Nervous System"},{"issue":"5","key":"10.1002\/14651858.CD001447.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1055\/s-2007-1017633","article-title":"Open-label trial of riluzole 50 mg b.i.d. in treatment of amyotrophic lateral sclerosis (ALS)","volume":"26","author":"Pongratz","year":"1999","journal-title":"Aktuelle Neurologie"},{"issue":"4","key":"10.1002\/14651858.CD001447.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1001\/archneur.55.4.526","article-title":"An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole","volume":"55","author":"Riviere","year":"1998","journal-title":"Archives of Neurology"},{"issue":"9046","key":"10.1002\/14651858.CD001447.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0140-6736(05)60977-4","article-title":"Effects of riluzole on symptom progression in amyotrophic lateral sclerosis","volume":"349","author":"Sojka","year":"1997","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD001447.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1468-1331.2006.01575.x","article-title":"Riluzole and amyotrophic lateral sclerosis survival: a population based study in Southern Italy","volume":"14","author":"Zoccolella","year":"2007","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD001447.pub3-BIB0018|cit18","unstructured":"Booth-Clibborn N Best L Stein K Riluzole for motor neurone disease Southampton: Wessex Institute for Health Research & Development (DEC Report 73) 1997"},{"issue":"1","key":"10.1002\/14651858.CD001447.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1579-2129(06)60113-4","article-title":"Strong suspicion of lung toxicity due to riluzole","volume":"42","author":"Border\u00edas-Clau","year":"2006","journal-title":"Archivos de Bronconeumologia"},{"key":"10.1002\/14651858.CD001447.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S1474-4422(05)70326-4","article-title":"Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial","volume":"5","author":"Bourke","year":"2006","journal-title":"Lancet Neurology"},{"issue":"Suppl","key":"10.1002\/14651858.CD001447.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/0022-510X(94)90191-0","article-title":"El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases\/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial \"Clinical limits of amyotrophic lateral sclerosis\" workshop contributors","volume":"124","author":"Brooks","year":"1994","journal-title":"Journal of Neurological Sciences"},{"key":"10.1002\/14651858.CD001447.pub3-BIB0022|cit22","first-page":"60","article-title":"Survival in non-riluzole treated amyotrophic lateral sclerosis (ALS) - Motor neuron disease (MND) patients with disease onset before and since 1996 is identical: a clinic-based epidemiological study","volume":"2","author":"Brooks","year":"2001","journal-title":"ALS and other motor neuron diseases"},{"issue":"8","key":"10.1002\/14651858.CD001447.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1212\/01.WNL.0000082385.33604.1D","article-title":"Hypersensitivity pneumonitis possibly caused by riluzole therapy in ALS","volume":"61","author":"Cassiman","year":"2003","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001447.pub3-BIB0024|cit24","unstructured":"Chilcott J Golightly P Jefferson D McCabe CJ Walters S The use of riluzole in the treatment of Amyotrophic Lateral Sclerosis (Motor Neurone Disease). Working Group on Acute Purchasing Trent Institute for Health Services Research, Universities of Leicester, Nottingham and Sheffield 1997"},{"key":"10.1002\/14651858.CD001447.pub3-BIB0025|cit25","unstructured":"Committee for Proprietary Medicinal Products European Public Assessment Report (EPAR) Rilutek The European Agency for the Evaluation of Medicinal Products"},{"key":"10.1002\/14651858.CD001447.pub3-BIB0026|cit26","doi-asserted-by":"crossref","DOI":"10.1002\/9780470712184.ch8","article-title":"Chapter 8: Assessing risk of bias in included studies","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2008"},{"issue":"2","key":"10.1002\/14651858.CD001447.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta5020","article-title":"The clinical effectiveness and cost-effectiveness of riluzole for motor neurone disease: a rapid and systematic review","volume":"5","author":"Stewart","year":"2001","journal-title":"Health Technology Assessment"},{"issue":"9-10","key":"10.1002\/14651858.CD001447.pub3-BIB0028|cit28","first-page":"185","article-title":"Riluzole and ALS therapy","volume":"146","author":"Hugon","year":"1996","journal-title":"Weiner Medizinische Wochenschrift"},{"key":"10.1002\/14651858.CD001447.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1212\/WNL.47.6_Suppl_4.251S","article-title":"ALS therapy: targets for the future","volume":"47","author":"Hugon","year":"1996","journal-title":"Neurology"},{"issue":"12","key":"10.1002\/14651858.CD001447.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1212\/WNL.39.12.1635","article-title":"A double-blind, placebo-controlled trial of high doses of gangliosides in amyotrophic lateral sclerosis","volume":"39","author":"Lacomblez","year":"1989","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001447.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1080\/17482960701223030","article-title":"Efficacy of riluzole: Who are the patients enrolled in the studies?","volume":"8","author":"Logroscino","year":"2007","journal-title":"Amyotrophic Lateral Sclerosis"},{"issue":"5","key":"10.1002\/14651858.CD001447.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1212\/WNL.46.5.1442","article-title":"Relationship of the Tufts Quantitative Neuromuscular Exam (TQNE) and the Sickness Impact Profile (SIP) in measuring progression of ALS","volume":"46","author":"McGuire","year":"1996","journal-title":"Neurology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD001447.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1007\/BF03160577","article-title":"The Riluzole Early Access Programme: descriptive analysis of 844 patients in France. ALS\/Riluzole Study Group III","volume":"244","author":"Meininger","year":"1997","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/14651858.CD001447.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/14660820410019602","article-title":"Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials","volume":"5","author":"Meininger","year":"2004","journal-title":"Amyotrophic lateral sclerosis and other motor neuron disorders"},{"issue":"4 Suppl 2","key":"10.1002\/14651858.CD001447.pub3-BIB0035|cit35","first-page":"S86","article-title":"Clinical trials of riluzole in patients with amyotrophic lateral sclerosis","volume":"47","author":"Miller","year":"1996","journal-title":"Neurology"},{"issue":"7","key":"10.1002\/14651858.CD001447.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1212\/WNL.52.7.1311","article-title":"Practice parameter: The care of the patient with amyotrophic lateral sclerosis (an evidence-based review)","volume":"52","author":"Miller","year":"1999","journal-title":"Neurology"},{"issue":"15","key":"10.1002\/14651858.CD001447.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1212\/WNL.0b013e3181bc0141","article-title":"Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"73","author":"Miller","year":"2009","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001447.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1212\/WNL.49.3.657","article-title":"Practice advisory on the treatment of amyotrophic lateral sclerosis with riluzole","volume":"49","author":"Quality Standards Subcommittee of the American Academy of Neurology","year":"1997","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001447.pub3-BIB0039|cit39","unstructured":"National Institute for Clinical Excellence Guidance on the use of riluzole (Rilutek) for the treatment of motor neurone disease Technology Appraisal Guidance 2001"},{"issue":"24","key":"10.1002\/14651858.CD001447.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"3","key":"10.1002\/14651858.CD001447.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0168-8278(99)80115-9","article-title":"Acute hepatitis after riluzole administration","volume":"30","author":"Remy","year":"1999","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD001447.pub3-BIB0042|cit42","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2011"},{"issue":"7","key":"10.1002\/14651858.CD001447.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1111\/j.1572-0241.2001.03982.x","article-title":"Riluzole-induced acute pancreatitis","volume":"96","author":"Rodrigo","year":"2001","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD001447.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0959-4388(96)80103-6","article-title":"Therapeutic horizons for amyotrophic lateral sclerosis","volume":"6","author":"Rothstein","year":"1996","journal-title":"Current Opinion in Neurobiology"},{"issue":"9","key":"10.1002\/14651858.CD001447.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1056\/NEJM199403033300911","article-title":"Riluzole for the treatment of amyotrophic lateral sclerosis - too soon to tell?","volume":"330","author":"Rowland","year":"1994","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1002\/14651858.CD001447.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1212\/01.wnl.0000249182.09143.20","article-title":"An acute, life-threatening, hypersensitivity reaction to riluzole","volume":"67","author":"Sorenson","year":"2006","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD001447.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1212\/WNL.50.1.66","article-title":"Prognostic indicators of survival in ALS","volume":"50","author":"Stambler","year":"1998","journal-title":"Neurology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD001447.pub3-BIB0048|cit48","first-page":"43","article-title":"Riluzole and prognosis in ALS: Findings of the Irish ALS register over a five year study period (1999-2000)","volume":"2","author":"Traynor","year":"2001","journal-title":"Amyotrophic lateral sclerosis and other motor neuron disorders"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD001447.pub3-BIB0049|cit49","first-page":"43","article-title":"The Kings' Database 1999-2000: an analysis of the effect on survival of interventions in amyotrophic lateral sclerosis","volume":"2","author":"Turner","year":"2001","journal-title":"Amyotrophic lateral sclerosis and other motor neuron disorders"},{"issue":"9","key":"10.1002\/14651858.CD001447.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1212\/01.WNL.0000123015.48097.9A","article-title":"Riluzole-induced neutropenia","volume":"62","author":"Weber","year":"2004","journal-title":"Neurology"},{"issue":"9030","key":"10.1002\/14651858.CD001447.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0140-6736(96)03181-9","article-title":"Riluzole","volume":"348","author":"Wokke","year":"1996","journal-title":"Lancet"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD001447.pub3\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T20:08:31Z","timestamp":1744574911000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD001447.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Neuromuscular Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,3,14]]},"references-count":51,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2012,3]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd001447.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,14]]}}}